Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals has purchased Ascent Pharmahealth, the Australia and Southeast Asia generic pharmaceutical business of Strides Arcolab.
Subscribe to our email newsletter
As per the agreement, Watson acquired Ascent Pharmahealth for AU$375 million (approximately $393 million) in cash.
Watson expects the deal to be immediately accretive to 2012 non-GAAP earnings.
Ascent markets a broad portfolio of generics, brands, branded-generic and over-the-counter (OTC) and dermatology and skin care products in Australia with approximately 14% market share.
Watson president and CEO Paul Bisaro said this acquisition establishes Watson among the leaders in the AU$12 billion Australian pharmaceutical market, where the generic market is growing at approximately 8%.